The automated Celsee PREP400 is designed for hands-free CTC capture and characterization
Celsee Diagnostics, an innovator in microfluidic rare-cell isolation, characterization and retrieval platforms announced today the receipt of an additional US patent for their single cell capture and analysis technologies.
U.S. Patent No. 9707562 B2, “System for Capturing and Analyzing Cells”, applies to the Celsee PREP400 platform and covers the embodiment of the process. The Celsee PREP400 automates CTC capture and isolation allowing laboratory personnel to load test samples and walk away; sample-to-result processing. The Celsee PREP400 processes the primary sample capturing CTCs in a microfluidic chip then treats the captured cells with Celsee Diagnostics’ reagents, pre-loaded in reagent cartridges with all the components required to complete an immunochemistry test. After the cells have been isolated and characterized the slide can be transferred to the Celsee ANALYZER imaging system for analysis, or if desired, analyzed on a confocal or fluorescent microscope.
“The issuance of this patent is timely as we start to implement research and development to expand the functionality of the PREP400 platform for other applications, such as the automated capture and analysis of single cells in our SingleCell nanowell chip,” said Celsee Diagnostics’ President and Chief Executive Officer Kalyan Handique.
About Celsee Diagnostics
Celsee Diagnostics, a privately-held company, develops, manufactures, and markets innovative, integrated microfluidic systems for rare- and single-cell isolation, analysis, and enumeration for Oncology/Immuno-Oncology life science and clinical research applications. The label-free Celsee PREP100 and PREP400 platforms perform all the required processing steps to isolate and execute single-cell analysis including immunochemistry, DNA FISH and mRNA FISH, while the Celsee ANALYZER scans and analyzes the prepared microfluidic chip automatically. The Celsee PREP SingleCell platform integrates isolation, staining and retrieval providing an unprecedented yield, almost 100%, of viable cells for culture, PCR or NGS at a cost of one-tenth that of competitive systems. Platforms can be used alone or in tandem in a streamlined workflow.